BeOne Medicines Ltd. Enters Material Definitive Agreement

TL;DR

BeOne Medicines just signed a big deal, creating a new financial obligation.

AI Summary

On November 13, 2025, BeOne Medicines Ltd. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as BeiGene, Ltd. until August 19, 2015, is incorporated in Switzerland and its principal executive offices are located in Basel.

Why It Matters

This filing indicates a significant new financial commitment or obligation for BeOne Medicines Ltd., which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce financial risks and operational changes that warrant careful monitoring.

Key Players & Entities

• BeOne Medicines Ltd. (company) — Registrant
• November 13, 2025 (date) — Date of earliest event reported
• BeiGene, Ltd. (company) — Former company name
• August 19, 2015 (date) — Date of name change
• Switzerland (location) — Jurisdiction of incorporation and principal executive offices location
• Basel (location) — City of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share ONC The NASDAQ Global Selec
• $140 million — ity in an aggregate principal amount of $140 million (the "B1 Revolving Loan Facility"); a
• $560 million — ity in an aggregate principal amount of $560 million (the "B2 Term Loan Facility" and, toget
• $300 million — egate principal amount of approximately $300 million (the "A Loan Facility") (collectively,
• $700 million — ties to be increased up to a maximum of $700 million in the aggregate, subject to the terms
• $2.7 billion — s' equity of the Group of not less than $2.7 billion; (iv) a minimum cash balance held outsi
• $500.0 million — RC by the Company and the Guarantors of $500.0 million; (v) a maximum financial indebtedness o
• $2.0 billion — pany and its subsidiaries not to exceed $2.0 billion; and (vi) a maximum financial indebtedn

Filing Documents

• bgne-20251113.htm (8-K) — 52KB
• 0001651308-25-000148.txt ( ) — 170KB
• bgne-20251113.xsd (EX-101.SCH) — 2KB
• bgne-20251113_lab.xml (EX-101.LAB) — 21KB
• bgne-20251113_pre.xml (EX-101.PRE) — 12KB
• bgne-20251113_htm.xml (XML) — 3KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. Entry into Facilities Agreement On November 13, 2025 (November 14, 2025 Hong Kong time), BeOne Medicines Ltd. (the "Company" and, together with its subsidiaries, the "Group") entered into the Facilities Agreement (the "Facilities Agreement"), by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors (the "Guarantors"), (ii) The Hongkong and Shanghai Banking Corporation Limited ("HSBC"), as global coordinator, original mandated lead arranger and bookrunner, agent and security agent, and (iii) certain financial institutions listed in the Facilities Agreement, as lenders. The Facilities Agreement provides the Company with senior secured financing consisting of: a U.S. dollar-denominated, B1 revolving loan facility in an aggregate principal amount of $140 million (the "B1 Revolving Loan Facility"); a U.S. dollar-denominated, B2 term loan facility in an aggregate principal amount of $560 million (the "B2 Term Loan Facility" and, together with the B1 Revolving Loan Facility, the "B Loan Facilities"); and a Renminbi-denominated, A term loan facility in an aggregate principal amount of approximately $300 million (the "A Loan Facility") (collectively, the "Loan Facilities"). The Facilities Agreement includes an uncommitted accordion feature that allows, under certain circumstances, the size of the B Loan Facilities to be increased up to a maximum of $700 million in the aggregate, subject to the terms and conditions of the Facilities Agreement. However, given that the B Loan Facilities are fully subscribed and limited to a combined maximum of $700 million in the aggregate, the Company does not expect to exercise this feature in the foreseeable future. The A Loan Facility matures 36 months after the first utilization date of such facility (the "First Facility A Utilization Date") and, unless extended, the B Loan Facilities mature 24 months after the first utilizati

Use of Proceeds

Use of Proceeds In accordance with the Facilities Agreement: the Company shall apply all the amounts provided by the A Loan Facility for general corporate purposes, including: (a) financing the general working capital requirements of the Group, (b) refinancing the Existing Offshore Financial Indebtedness (as defined in the Facilities Agreement) of the Group, and (c) the payment of any fees and expenses in relation to the Loan Facilities; and the Company shall apply all the amounts provided by the B Loan Facilities for general corporate purposes, including: (a) financing the general working capital requirements of the Group, (b) refinancing the Existing Offshore Financial Indebtedness of the Group, (c) the payment of any fees and expenses in relation to the Loan Facilities, and (d) if and to the extent not prohibited by applicable laws and regulations, reimbursing any payment made by any Group member for any of the purposes listed above. Security and Guarantees Interest Rate, Fees & Events of Default The A Loan Facility is subject to an interest rate equal to the Reference Rate (RMB) (as defined in the Facilities Agreement) plus a mar

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the utilization of the Loan Facilities, the use of proceeds under the Facilities Agreement and the exercise of certain features under the Facilities Agreement. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the Company's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the Company's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; the Company's ability to obtain and maintain protection of intellectual property for its medicines and technology; the Company's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; the Company's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; the Company's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in the Company's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the U.S. Securities and Exchange Commission. All information herein is as of the date set forth above, and the Company undertakes no duty to update such information unless required by law. SIGNATURE Pursuant to the requirements of the Securiti

View Full Filing

View this 8-K filing on SEC EDGAR